Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether they will place in the Library of the House a copy of any findings or outcomes of the exploratory work completed by NHS England that is described in the National Data Guardian’s Annual Report for 2023–2024 on the topic of adding a patient-facing function to GP Connect to enable people to see who has accessed their health records.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
Following the initial discussion with the National Data Guardian, NHS England decided not to pursue the topic of adding a patient-facing function to GP Connect. It would have had a limited application and been technically and legally complex to implement, as noted in section 6.7.4 of the National Data Guardian 2023-2024 report, and would not have provided sufficient benefit, additional to the existing function of Subject Access Requests. There was, therefore, no exploratory work completed on this subject.
There are multiple ways for a patient’s record to be accessed. Any patient-facing feature needs to take all these different routes into account and, as noted by the National Data Guardian, NHS England is considering whether this functionality might be possible in the Government’s plans for a single care record.
Asked by: Paul Davies (Labour - Colne Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what plans his Department has to tackle barriers teenagers and young adults with cancer face in accessing clinical trials.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
To maximise our potential to be a world leader and develop a more competitive, efficient and accessible clinical research system, the Department is committed to implementing recommendations from the Lord O'Shaughnessy independent review of commercial clinical trials in full.
The Department funds research and research infrastructure, which supports patients and the public to participate in high-quality research across the United Kingdom, through the National Institute of Health and Care Research (NIHR). For children and young people with cancer, this infrastructure includes the Experimental Cancer Medicine Centres, co-funded by the NIHR, Cancer Research UK and the Little Princess Trust, which act as a UK-wide network, bringing together world-leading laboratory and clinical researchers to test new treatments for adults and children with cancer. This includes 12 paediatric phase I/II centres, which function as a single virtual centre to improve patient recruitment and expand geographical access to cancer treatments, tackling some of the barriers to teenagers and young adults accessing cancer clinical trials.
The Department is committed to ensuring clinical trials are people-centred and more accessible, including for teenagers and young adults with cancer. For example, the NIHR provides an online service called 'Be Part of Research' which promotes participation in health and care research by allowing users to search for relevant studies. Young adults aged 18 or over, can consent to be matched to and contacted about relevant studies.
Asked by: Al Pinkerton (Liberal Democrat - Surrey Heath)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the potential merits of(a) the utilisation of psilocybin-based treatments for mental health conditions and (b) commissioning further research into the therapeutic applications of psychedelic drugs.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department recognises that the use of psychedelic-assisted psychotherapies, such as psilocybin, to treat mental illness is gaining attention both within the medical and scientific communities, as well as across the public more broadly. However, there is no proven medical use for psilocybin in the United Kingdom, and no such substance has yet been licensed as safe and effective in the treatment of mental health conditions. The National Institute for Health and Care Research (NIHR) is supporting psilocybin research via the NIHR King’s Clinical Research Facility, the NIHR Oxford Health Clinical Research Facility, and the NIHR Maudsley Biomedical Research Centre, where researchers are developing and evaluating the efficacy and safety of psilocybin therapies.
Asked by: Luke Akehurst (Labour - North Durham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to introduce (a) mandatory training and (b) policies on surgical fires within all NHS hospital settings.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
In 2023, the Centre for Perioperative Care published revised National Safety Standards for Invasive Procedures (NatSSIPs2). The standards were designed to reduce misunderstandings or errors, and to improve team cohesion. The NatSSIPs2 include a requirement for providers to have a local fire safety policy, in order to minimise the risk of surgical fires, and a management plan in the event of one occurring.
The NatSSIPs2 should form the basis of improvement work, inspections, and curricula. The standards support National Health Service organisations in providing safer care, and to reduce the number of patient safety incidents related to invasive procedures in which surgical fires can occur.
At this time, the Department has no plans to make training mandatory or to introduce further policies in relation to surgical fires
Asked by: Baroness Coussins (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether they plan to amend the Accessible Information Standard so that it is aligned with the recommendation of Healthwatch England to cover the needs of those who speak little or no English.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
We have no current plans to make such a change to the Accessible Information Standard (AIS). The AIS aims to make sure that people who have a disability, impairment or sensory loss get information that they can access and understand. NHS England is responsible for the AIS and has completed a review as part of the revision of the standard.
Spoken and community languages are specifically excluded from the AIS and have not been included as part of its review due to the legislative basis of the AIS and its focus on meeting the needs of disabled people.
The General Medical Council’s guidance states that all possible efforts must be made to ensure effective communication with patients. This includes arrangements to meet patients’ communication needs in languages other than English. Where language is a problem in discussing health matters, NHS England and NHS Scotland’s guidance states that a professional interpreter should always be offered.
NHS England is aware of safety investigations and other issues relating to translation services and has completed a strategic review and options appraisal to identify if and how NHS England can support improvements in the commissioning and delivery of community language translation and interpretation services.
Asked by: Lord Cashman (Non-affiliated - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether the Secretary of State for Health and Social Care plans to meet with parents of trans children, as requested in correspondence from Lord Cashman to his office since July.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
My Rt. Hon. Friend, the Secretary of State for Health and Social Care has held constructive roundtable discussions with a group of children and young people, and their parents, with lived experience of gender dysphoria and incongruence.
The Government remains committed to listening to the LGBT+ community. Department officials will write to you on how best to take forward your request.
Asked by: Neil O'Brien (Conservative - Harborough, Oadby and Wigston)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate he has made of the average time taken for deaths to be reviewed under the national medical examiner system since 9 September 2024; and if he will make an assessment of the potential impact of the time taken for deaths to be reviewed on the time taken to arrange funerals.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is monitoring the impact of the death certification reforms, which came into legal effect on 9 September 2024. The median time taken to register a death since the introduction of the statutory medical examiner system in England and Wales is eight days. This figure is for all deaths, as it includes those certified by a doctor and those investigated by a coroner. The median time taken to register a death varies depending on the type of certification. Deaths certified by a doctor, that comprise approximately 80% of deaths registered each week, had a median time to registration of seven days. The Department has not conducted a separate review of the time taken to arrange funerals, which can depend on a number of external factors.
The core purposes of the death certification reforms are to introduce scrutiny of the cause of death to detect and deter malpractice, to improve reporting, and crucially to put the bereaved at the centre of the process by offering a conversation with the medical examiner about the cause of death. The expectation on doctors and medical examiners is clear, that they should complete certification as quickly and efficiently as possible, and the Department is working with all stakeholders to make sure this is the case.
Asked by: Bobby Dean (Liberal Democrat - Carshalton and Wallington)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to continue funding for the opt-out blood-borne virus testing programme at (a) St George's, Epsom and (b) St Helier Hospitals and Health Group beyond March 2025.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
On 28 November 2024, the Prime Minister announced a further £27 million of funding for the continuation of the HIV Emergency Department opt-out testing programme for 2025/26. As part of the extension, more than 90 sites will be offered funding to continue or begin the roll out of HIV opt out testing until March 2026, including St George's, Epsom, and St Helier hospitals.
NHS England will evaluate the costs and feasibility of further extending this programme regarding hepatitis B and C opt-out testing, once budgets for 2025/26 are confirmed, and expects to provide an update on their decision in the early new year.
There are currently no plans to extend opt-out HIV testing beyond emergency departments. However, the Department, together with the UK Health and Security Agency, and NHS England are working together in the development of a new HIV Action Plan, which will include a focus on scaling up HIV testing, and which we aim to publish in summer 2025.
Asked by: Luke Taylor (Liberal Democrat - Sutton and Cheam)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will take steps to increase diagnosis levels for genetic haemochromatosis.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
Genomic testing in the National Health Service in England is provided through the NHS Genomic Medicine Service (GMS) and delivered by seven NHS Genomic Laboratory Hubs. Genomic testing for genetic haemochromatosis is available through the NHS GMS for all patients in England who show an unexplained iron overload, suggestive of hereditary haemochromatosis, to aid in the diagnosis of the disease. Any healthcare professional who suspects their patient may have haemochromatosis can refer their patient for testing via their local NHS Clinical Genomic Service. Individuals can discuss with their healthcare professional, for instance their general practitioner, whether genomic testing is appropriate for them.
Asked by: Beccy Cooper (Labour - Worthing West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to expedite implementation of the recommendations from the Hughes report, published on 7 February 2024; and whether he plans to prioritise establishment of (a) interim payments and (b) a valporate specialist unit to support those affected.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is carefully considering the valuable work done by the Patient Safety Commissioner and the resulting Hughes Report. The report sets out options for redress for those harmed by valproate and pelvic mesh, including proposals for a financial scheme and for the establishment of a valproate specialist unit. The Government will be providing an update to the Patient Safety Commissioner’s Report at the earliest opportunity.